Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 35.3% in March

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large decrease in short interest in March. As of March 13th, there was short interest totaling 17,367 shares, a decrease of 35.3% from the February 26th total of 26,832 shares. Based on an average daily volume of 18,421 shares, the short-interest ratio is presently 0.9 days. Currently, 0.4% of the company’s stock are short sold.

Galmed Pharmaceuticals Stock Performance

Shares of GLMD stock opened at $0.50 on Friday. Galmed Pharmaceuticals has a 52-week low of $0.41 and a 52-week high of $2.68. The stock has a market cap of $2.77 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. The firm’s 50-day moving average is $0.65 and its 200-day moving average is $0.99.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Galmed Pharmaceuticals has an average rating of “Reduce”.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.